Last reviewed · How we verify
Hepatic Arterial Blood Flow Modulation in Patients With Hepatocellular Carcinoma: Influence of Intra-arterial Norepinephrine Assessed With CT Perfusion
Dr Rajan is investigating a new method to improve local treatment of liver cancer. There is evidence that a drug, norepinephrine (NE), has the ability to shrink down normal liver blood vessels, but leave tumor vessels wide open. In patients with primary liver cancer, NE will be injected directly in the artery that nourishes the liver and the tumor. Real time blood flow will be measured using an advanced CT scanner to demonstrate the NE effect on blood vessels. If Dr Rajan's hypothesis is confirmed, this drug has great potential to benefit patients during local delivery of chemotherapy in the liver artery, diverting it away from normal liver and towards the tumor, resulting in less complications and improved tumor kill.
Details
| Lead sponsor | University Health Network, Toronto |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 10 |
| Start date | 2016-01 |
| Completion | 2020-12-01 |
Conditions
- Hepatocellular Carcinoma
Interventions
- CT perfusion
- Norepinephrine intra-arteriel/hepatic
Primary outcomes
- Liver blood flow — 1 minute following injection
Liver blood flow as measured with CT perfusion
Countries
Canada